{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T05:49:12Z","timestamp":1773208152123,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/s1470-2045(13)70102-5","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T03:10:20Z","timestamp":1366168220000},"page":"490-499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":701,"title":["Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial"],"prefix":"10.1016","volume":"14","author":[{"given":"Florian","family":"Lordick","sequence":"first","affiliation":[]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[]},{"given":"Hyun-Cheol","family":"Chung","sequence":"additional","affiliation":[]},{"given":"Pamela","family":"Salman","sequence":"additional","affiliation":[]},{"given":"Sang Cheul","family":"Oh","sequence":"additional","affiliation":[]},{"given":"Gy\u00f6rgy","family":"Bodoky","sequence":"additional","affiliation":[]},{"given":"Galina","family":"Kurteva","sequence":"additional","affiliation":[]},{"given":"Constantin","family":"Volovat","sequence":"additional","affiliation":[]},{"given":"Vladimir M","family":"Moiseyenko","sequence":"additional","affiliation":[]},{"given":"Vera","family":"Gorbunova","sequence":"additional","affiliation":[]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[]},{"given":"Akira","family":"Sawaki","sequence":"additional","affiliation":[]},{"given":"Ilhan","family":"Celik","sequence":"additional","affiliation":[]},{"given":"Heiko","family":"G\u00f6tte","sequence":"additional","affiliation":[]},{"given":"Helena","family":"Melez\u00ednkov\u00e1","sequence":"additional","affiliation":[]},{"given":"Markus","family":"Moehler","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(13)70102-5_bib1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/egh.11.103","article-title":"Management of advanced gastric cancer","volume":"6","author":"Price","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004064.pub3","article-title":"Chemotherapy for advanced gastric cancer","volume":"3","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S1470-2045(13)70102-5_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Kang","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","article-title":"Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study","volume":"10","author":"Boku","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"suppl 4","key":"10.1016\/S1470-2045(13)70102-5_bib8","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1365-2559.2008.03021.x","article-title":"EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number","volume":"52","author":"Kim","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/S1470-2045(13)70102-5_bib10","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdq632","article-title":"Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study","volume":"22","author":"Bokemeyer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(13)70102-5_bib13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(13)70102-5_bib14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/sj.bjc.6604861","article-title":"Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer","volume":"100","author":"Han","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib15","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1093\/annonc\/mdq591","article-title":"Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study","volume":"22","author":"Moehler","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjc.6605521","article-title":"Cetuximab plus oxaliplatin\/leucovorin\/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"102","author":"Lordick","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s10637-009-9363-0","article-title":"A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and\/or recurrent advanced gastric cancer","volume":"29","author":"Kim","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1016\/S1470-2045(13)70102-5_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/S1470-2045(13)70102-5_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/S1470-2045(13)70102-5_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","article-title":"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study","volume":"13","author":"Pirker","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib21","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/1097-0258(20001015)19:19<2595::AID-SIM562>3.0.CO;2-M","article-title":"A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data","volume":"19","author":"Bonetti","year":"2000","journal-title":"Stat Med"},{"key":"10.1016\/S1470-2045(13)70102-5_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(13)70102-5_bib23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"Al-Batran","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib25","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib26","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2014pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/annonc\/mdn166","article-title":"Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction","volume":"19","author":"Dank","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib28","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.bjc.6605319","article-title":"Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)","volume":"101","author":"Pinto","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib29","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II\/III REAL-3 trial","volume":"28","author":"Okines","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","author":"Waddell","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/annonc\/mdp269","article-title":"A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction","volume":"21","author":"Moehler","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib32","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdp047","article-title":"Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer","volume":"20","author":"Okines","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib33","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/S1470-2045(13)70102-5_bib34","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00280-012-1898-7","article-title":"Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters","volume":"70","author":"Ku","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib36","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/1471-2407-11-509","article-title":"Biomarker analysis of cetuximab plus oxaliplatin\/leucovorin\/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"11","author":"Luber","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib38","article-title":"Predictive value of EGFR expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies","author":"Licitra","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/S1470-2045(13)70102-5_bib39","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib40","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70102-5_bib41","first-page":"57","article-title":"HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value\u2014conclusions from 924 cases of two independent series","volume":"32","author":"Grabsch","year":"2010","journal-title":"Cell Oncol"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204513701025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204513701025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:07:47Z","timestamp":1761458867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204513701025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S1470204513701025"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(13)70102-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006635.793477611","asserted-by":"object"}]},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(13)70102-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(13)70133-5","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}